Risk Based 2020 - Risk Based Verification and/or Validation to meet US FDA CGMP and ISO 13485 Requirements
Topics/Call fo Papers
Webinar for a discussion of the webinar how to review a company's Validation Master Plan for major cGMP deficiencies. Review hazard and risk management tools per ISO 14971 and ICH Q9.
FDA Warning Letters and high-profile recalls indicate major cGMP deficiencies in device and pharma companies on both sides of the Atlantic. One major failing is lack of sufficient or targeted risk-based V&V planning.
Verification or Validation -- Current regulatory expectations.
The Master Validation Plan and the Individual V&V Plan.
Speaker:
John E. Lincoln is Principal of J. E. Lincoln and Associates LLC, a consulting company, with over 32 years experience in U.S. FDA-regulated industries, 18 of which as a full time independent FDA-regulated industry consultant.
FDA Warning Letters and high-profile recalls indicate major cGMP deficiencies in device and pharma companies on both sides of the Atlantic. One major failing is lack of sufficient or targeted risk-based V&V planning.
Verification or Validation -- Current regulatory expectations.
The Master Validation Plan and the Individual V&V Plan.
Speaker:
John E. Lincoln is Principal of J. E. Lincoln and Associates LLC, a consulting company, with over 32 years experience in U.S. FDA-regulated industries, 18 of which as a full time independent FDA-regulated industry consultant.
Other CFPs
- 4th International Conference on Natural Language Processing and Trends (NATAP 2021)
- 7th International Conference on Data Mining and Applications (DMAP 2021)
- The World of Global Cash Flow: Is There Enough to Cover All Debts?
- Who Am I? The role of Human Capital Assets in the Global Workplace
- Wage and Hour - Complying with the Fair Labor Standards Act with a Summary of the New Regulations
Last modified: 2020-10-30 20:02:20